Avid Bioservices Inc (CDMO)

[entdoc]

bigworld, one caveat: testing on nearly-deads is necessary in case there is a serious side-effect in a new drug that might hasten one's demise. That group is used for testing to minimize potential downside, not necessarily to maximize upside. Once you have the go-ahead for "safe-in-humans", there are all kinds of potential in this particular (anti-PS)arena. The obvious concern is the anti-PS syndrome, and NObody wants to be trying a medication for any indication when an obvious, serious possible side-effect is looming. That hurdle has been passed with Bavi, in spades, and now efficacy for some application must be established. Safety apparently remains more an issue with Cotara than efficacy...if I am guessing right.